Acepodia, Inc. (TPEX:6976)

Market Cap	10.61B
Revenue (ttm)	427.00K
Net Income (ttm)	-496.75M
Shares Out	573.68M
EPS (ttm)	-0.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	226,102
Average Volume	477,553
Open	18.50
Previous Close	18.50
Day's Range	18.30 - 18.65
52-Week Range	13.80 - 28.90
Beta	n/a
RSI	53.52
Earnings Date	May 12, 2025

About Acepodia

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It links tumor targeting antibodies to its proprietary immune cells, such as gamma delta 2 T cells to create novel ACE therapies. In addition, the company develops ACE 1831 targeting CD20 that is in phase 1 clinical trial; ACE 2016 targeting EGFR, which is in preclinical study; ACE1708; and ACE1702 targeting HER2 that is in phase 1 clinical trial....

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Shih-Chia Hsiao
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6976

Financial Performance

In 2024, Acepodia's revenue was 427,000, a decrease of -97.43% compared to the previous year's 16.59 million. Losses were -496.75 million, -39.22% less than in 2023.